Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)

NCT01181167 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT01181167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01181167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2009
Completion date
March 31, 2010
Enrollment
610 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prevention, venous thromboembolism